Maven Securities’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Maven Securities’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,000	Closed	-$272K	–	1245
2023 Q2	$272K	Sell	25,000 -10,000	-29%	-$85.6K	﹤0.01%	759
2023 Q1	$242K	Hold	35,000	–	–	0.01%	846
2022 Q4	$139K	Hold	35,000	–	–	﹤0.01%	792
2022 Q3	$233K	Hold	35,000	–	–	﹤0.01%	1010
2022 Q2	$169K	Hold	35,000	–	–	0.01%	855
2022 Q1	$327K	Buy	35,000 +10,000	+40%	+$99.3K	0.01%	681
2021 Q4	$297K	Hold	25,000	–	–	0.01%	695
2021 Q3	$285K	Hold	25,000	–	–	0.01%	852
2021 Q2	$463K	Hold	25,000	–	–	0.02%	694
2021 Q1	$379K	Buy	25,000 +12,500	+100%	+$181K	0.02%	752
2020 Q4	$154K	Sell	12,500 -525,800	-98%	-$7.33M	0.02%	516
2020 Q3	$6.89M	Buy	538,300 +330,275	+159%	+$2.85M	0.57%	35
2020 Q2	$2.11M	Buy	+208,025	New	+$1.91M	0.14%	131

Other funds holding MRNS

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Maven Securities's MRNS Position: Q3 2023 in Review

Maven Securities sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2023, closing a stake of 25,000 shares — an estimated $272K sold.

Maven Securities first reported a position in MRNS in Q2 2020 and held it in 13 quarters. The position peaked at $6.89M in Q3 2020. 104 funds tracked by Wall St. Rank hold MRNS as of Q3 2023.

Maven Securities reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
Maven Securities sold 25,000 Marinus Pharmaceuticals, Inc shares in Q3 2023, an estimated $272K.
Maven Securities first reported a position in Marinus Pharmaceuticals, Inc in Q2 2020 and held it in 13 quarters.
Maven Securities's Marinus Pharmaceuticals, Inc position peaked at $6.89M in Q3 2020.
104 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2023.

Based on Maven Securities's 13F filing for Q3 2023, filed 13 Nov 2023.